Guizhou Xinbang Pharmaceutical Co Ltd (002390) — Financial Flexibility Index
Guizhou Xinbang Pharmaceutical Co Ltd (002390) has a Financial Flexibility Index of 0.15x as of September 2025. Free cash flow of CN¥244.63 Million (operating CF CN¥234.19 Million minus capex CN¥10.43 Million) represents 0% of total liabilities (CN¥1.62 Billion). Also explore Guizhou Xinbang Pharmaceutical Co Ltd equity growth rate to track the company's year-over-year net asset growth rate.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Guizhou Xinbang Pharmaceutical Co Ltd Financial Flexibility Index (2006–2024)
Historical Financial Flexibility Index trend for Guizhou Xinbang Pharmaceutical Co Ltd across 19 annual periods. Check Guizhou Xinbang Pharmaceutical Co Ltd (002390) strategic asset index to assess the company's strategic physical and investment asset allocation.
Annual Financial Flexibility Index for Guizhou Xinbang Pharmaceutical Co Ltd (2006–2024)
Year-by-year free cash flow to debt coverage for Guizhou Xinbang Pharmaceutical Co Ltd. For the full company profile including market capitalisation, see Guizhou Xinbang Pharmaceutical Co Ltd stock valuation.
| Year | Flexibility Index | Free Cash Flow (CNY) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2024 | 0.38x | CN¥759.84 Million | CN¥634.97 Million | CN¥2.01 Billion | ▼ -14.1% |
| 2023 | 0.44x | CN¥926.40 Million | CN¥790.62 Million | CN¥2.10 Billion | ▲ +60.3% |
| 2022 | 0.27x | CN¥749.58 Million | CN¥590.80 Million | CN¥2.73 Billion | ▲ +8.1% |
| 2021 | 0.25x | CN¥711.74 Million | CN¥457.97 Million | CN¥2.80 Billion | ▲ +29.8% |
| 2020 | 0.20x | CN¥880.20 Million | CN¥742.11 Million | CN¥4.49 Billion | ▼ -3.8% |
| 2019 | 0.20x | CN¥1.09 Billion | CN¥886.33 Million | CN¥5.37 Billion | ▲ +2475.8% |
| 2018 | 0.01x | CN¥44.96 Million | CN¥-218.56 Million | CN¥5.69 Billion | ▼ -93.5% |
| 2017 | 0.12x | CN¥636.77 Million | CN¥201.74 Million | CN¥5.20 Billion | ▲ +126.2% |
| 2016 | 0.05x | CN¥233.65 Million | CN¥-198.59 Million | CN¥4.31 Billion | ▼ -70.7% |
| 2015 | 0.19x | CN¥709.88 Million | CN¥217.40 Million | CN¥3.84 Billion | ▲ +509.0% |
| 2014 | 0.03x | CN¥84.04 Million | CN¥-198.60 Million | CN¥2.77 Billion | ▼ -41.6% |
| 2013 | 0.05x | CN¥23.46 Million | CN¥-21.34 Million | CN¥450.69 Million | ▼ -0.4% |
| 2012 | 0.05x | CN¥16.30 Million | CN¥-36.46 Million | CN¥311.99 Million | ▼ -75.6% |
| 2011 | 0.21x | CN¥56.61 Million | CN¥-39.87 Million | CN¥264.02 Million | ▼ -53.9% |
| 2010 | 0.47x | CN¥77.12 Million | CN¥2.50 Million | CN¥165.81 Million | ▲ +109.0% |
| 2009 | 0.22x | CN¥48.40 Million | CN¥41.75 Million | CN¥217.51 Million | ▲ +64.3% |
| 2008 | 0.14x | CN¥31.83 Million | CN¥24.86 Million | CN¥235.04 Million | ▼ -52.2% |
| 2007 | 0.28x | CN¥61.44 Million | CN¥32.49 Million | CN¥216.99 Million | ▲ +42.8% |
| 2006 | 0.20x | CN¥46.61 Million | CN¥7.35 Million | CN¥235.18 Million | — |